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ABSTRACT
Interstitial Cystitis/Painful Bladder Syndrome(IC/PBS) is a chronic inflammation
of the urinary bladder, consisting of irritative voiding symptoms; frequent and urgent
urination and pain referred to the pelvic region or the bladder upon filling, lack of other
pathology. The pathophysiology of interstitial cystitis (IC) is enigmatic. The impaired
urothelium of bladder and autoimmunity might lead the underlying pathology. One of the
shortcomings in IC/PBS research has been the lack of an appropriate animal model.
In the current study, we show that the bladder specific Uroplakin 3A (UPK3A)derived immunogenic UPK3A 65-84 peptide is capable of targeting experimental
autoimmune cystitis (EAC) in BALB/c mice. We determined an immunogenic peptide
from the known sequence of UPK3A based on having the binding motif for IAd MHC
class II molecules expressed in BALB/c mice. The highly antigen-specific proliferative
response to UPK3A 65-84 was determined by proliferation assays. Active immunization
with the UPK3A 65-84 peptide resulted in increased micturition frequency and decreased
urine output per micturition by FVC along with the increased pelvic pain response to von
Frey Filaments, and decrease intercontractile intervals, bladder compliance and bladder
capacity in CMG after 5 weeks of immunization compared to control group.
The recall responses of LNC to UPK3A 65-84 showed selectively activated CD4+
T-cells with a proinflammatory Th1-like phenotype. Immunocytochemical analysis
v

showed that immunization with UPK3A 65-84 peptide resulted in T-cell infiltration of
the bladder. The ratio of bladder weight to body weight was increased in EAC mice
simply showing bladder inflammation. The elevated gene expression levels of TNF-α,
IFN-γ, IL-17A, and IL-1β were confined to the bladder but not in other organs. T-cell
induction of EAC was identified by showing significantly increased micturition
frequency and decreased output per micturition by FVC along with the increased pelvic
pain response to von Frey monofilament stimulus after adoptive transfer of peptideactivated CD4+ T-cells into naïve BALB/c hosts.
Our study provides the creation of an advanced and more specific EAC model
manifesting all three major phenotypes of IC/PBS by inoculation of mice with, and
eliciting an immune response to, tissue specific peptide derived from the Uroplakin of the
bladder urothelium. These findings qualify this animal model as a contemporary model
for future exploration of pathogenesis and therapeutic intervention of IC/PBS.
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CHAPTER I
BACKGROUND AND INTRODUCTION

1.1. AUTOIMMUNITY
1.1.1. Immune System
The immune system is competent to recognize and horse effectively specific
immune response to the vast variety of foreign antigens, pathogens or cancer cells
without any damage to host itself. This amazing diversity of immune system is achieved
by somatic recombination and rearrangement of gene segments coding for B-cells,
antibody molecules, and T-cell receptors (TCR) (French, Laskov et al. 1989; Livak,
Burtrum et al. 2000; Li, Woo et al. 2004). The CD4+ CD8+ double positive (DP) cells
go into apoptosis if they do not recognize any antigens, and their TCRs bind high affinity
to self-peptide/MHC complex (Kappler, Roehm et al. 1987; McDuffie, Roehm et al.
1987). On the other hand, if the DP cells are acquainted with self-antigens or MHC with
low affinity, they enter into positive selection and alter to cytotoxic-T cells and T-helper
cells (Kappler, Roehm et al. 1987; McDuffie, Roehm et al. 1987). The immature T cells
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that recognize the self-antigens binding the Major Histocompatibility Complex(MHC)
molecules develop maturation (Robey and Fowlkes 1994).
These generated T-cells express very diverse set of TCRs. The positive selection
based on the MHCs narrows the T cells population in the periphery (Sospedra, FerrerFrancesch et al. 1998). The 3% of the differentiated T cells continue to exist after positive
and negative selection (Shortman, Egerton et al. 1990). The mature T cells travel to
spleen and lymphoid nodes where they are ready to act in response to foreign antigens.
One TCR cross-react with various peptides and this process is required to sustain immune
system with adequate flexibility to get used to an incessantly varying antigenic milieu
(Garcia and Teyton 1998; Mason 1998). A few T cells with the intermediate affinity to
self-antigen flee from the

thymic negative selection and are freed in to the

periphery(Jiang and Chess 2006).These escaped self-reactive T cells are competent for
self-peptide originated proliferative response and can transform into pathogenic effector
cells inducing autoimmunity(Mason and Powrie 1998; Kuchroo, Anderson et al. 2002;
Jiang and Chess 2006).

1.1.2. General Features of Autoimmunity
Autoimmunity is the outcome of impairment and breakdown of self –tolerance
mechanisms due to cause of genetic factors, environmental factors, bystander effect and
cross reactivity of infectious agents, Toll-Like Receptor (TLR) cross-linking (Romagnani
2006). The autoimmune disease leads broad changes of immune system along with
changes in cytokine profile and autoantibodies causing tissue injure and impaired
immune response(Winer and Winer 2012). Autoimmune response attacks the own self-
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antigens of body and leads continuous auto-reactivity to targeted tissues or organ causing
chronic inflammatory damage(Brower 2004). It is eminent that T-cells play a major role
in autoimmune diseases development and initiation via antigen-specific immune response
(O'Garra, Steinman et al. 1997) as seen in multiple sclerosis(Swanborg 1995), type 1
diabetes mellitus (Delovitch and Singh 1997), rheumatoid arthritis((Anthony and Haqqi
1999; Fitzpatrick, Green et al. 2011).
Genetic mutations can cause autoimmunity. The autoimmune poliendocrinopathy,
candidiasis, ectodermal dystrophy (APECED) is the result of genetic mutation of AIRE
gene in central tolerance mechanism (Peterson and Peltonen 2005), and autoimmune
lymphoproliferative syndrome (ALPS) is the outcome of mutations in Fas/FasL-mediated
apoptosis (Worth, Thrasher et al. 2006).
It was shown that ischemic injury and trauma could elicit autoimmune condition
as seen in post-traumatic uveitis (Rahi, Morgan et al. 1978) and orchitis after vasectomy
(Goldacre, Abisgold et al. 2006). Moreover, the infectious agent can cause autoimmunity
through eliciting sequestered auto-antigen (Miller, Vanderlugt et al. 1997) inducing the
inflammatory cytokines and co-stimulatory molecules (Klinman, Yi et al. 1996; InfanteDuarte, Horton et al. 2000) and also elicit T-cells by super antigens(Kearney, Pape et al.
1994).

1.1.3. Organ Specific Autoimmunity
While the systemic autoimmune diseases affect multiple organs, the organspecific autoimmune diseases mainly target one specific organ or tissue.

The

immunological reactivity to self-antigen mediated tissue or organ specific autoimmune
3

disorders have shown in several diseases. Autoimmune hepatitis(T-cell-mediated attack
on liver antigens), Hashimoto’s thyroiditis (Autoantibodies to thyroglobulin of thyroid
gland), Graves’ disease (Thyrotropin receptor autoantibodies, antibody to the thyroidstimulating hormone receptor ), type 1 diabetes(autoimmune response to pancreatic islets
beta cells) , Addison’s disease (autoimmunity against adrenal glands),rheumatoid
arthritis(autoimmune attack to synovial tissues of joints), multiple sclerosis(autoimmune
attack to central nervous system) and myasthenia gravis(antibody to the acetylcholine
receptor) are some of the more common organ-specific autoimmune conditions(Golub
1991; Gossard and Lindor 2012) (Chazenbalk, Portolano et al. 1993; Swanborg 1995;
King and Sarvetnick 1997; Anthony and Haqqi 1999) (Martin Martorell, Roep et al.
2002; Wilson 2011) (Ratliff, Klutke et al. 1995). Sjögren’s syndrome (autoimmune
attacks the exocrine glands) and systemic lupus erythematosus (SLE) (autoantibodies
Double-stranded DNA (dsDNA) are well-known examples of systemic autoimmune
diseases.

1.1.4. Experimental Organ-Specific Autoimmunity
The conception of the employing of experimental autoimmunity through the
stimulation of T-cell mediated targeted self-antigens has utilized to the establishment of
practical models of autoimmune conditions such as autoimmune encephalomyelitis
(EAE)(Tuohy, Lu et al. 1989; Yu, Johnson et al. 1996), autoimmune myocarditis (Janewit, Yu et al. 2002), autoimmune oophoritis(Altuntas, Johnson et al. 2006),autoimmune
hearing loss(Solares, Edling et al. 2004) and experimental autoimmune cystitis (EAC)
that imitates the phenotype of human interstitial cystitis(IC)(Lin, Liu et al. 2008;
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Altuntas, Daneshgari et al. 2011) . For development of organ specific autoimmunity, the
lyophilized animal whole organ tissue homogenate, proteins or peptides of targeted
organs were used. The animals are immunized with immunogenic antigen in a emulsion
of complete Freund’s adjuvant (CFA) which augments the inflammatory response to the
selected immunogenic protein or peptide. Myelin proteolipid protein (PLP), myelinassociated oligodendrocytic basic protein (MOBP), myelin oligodendrocyte glycoprotein
(MOG) are used for induction of EAE in animal that mimics human clinical aspects of
multiple sclerosis (Tuohy, Lu et al. 1989; Yu, Johnson et al. 1996; Kaushansky, ZilkhaFalb et al. 2007). The cardiac alpha-myosin heavy chain (CAMHC) is used for induction
of experimental autoimmune myocarditis (Jane-wit, Yu et al. 2002), inner ear specific
proteins cochlin (Coch) and β-tectorin are used for targeting experimental autoimmune
hearing loss (EAHL) in mice(Solares, Edling et al. 2004), and bladder specific uroplakin
2 protein is used for induction of experimental autoimmune cystitis(EAC)(Altuntas,
Daneshgari et al. 2011).

1.1.5. T Cells and Autoimmunity
The self-tolerance is preserved through the elimination of immature T cells that
recognize self -antigens in the thymus by negative selection (Kappler, Roehm et al.
1987), and T regulatory cells(Treg)(Sakaguchi, Sakaguchi et al. 1995), deletion by
apoptosis, T cell anergy (Jenkins and Schwartz 2009) in the periphery (Walker and Abbas
2002; Saeki and Iwasa 2011). Self-reactive T cells recognize and attack to own tissues or
organs that lead autoimmunity in the periphery (Seddon and Mason 1999; Jordan,
Boesteanu et al. 2001). Genetic mutations or deletions can also breakdown the tolerance
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and contribute the development of autoimmunity (Abbas, Lohr et al. 2004). Some autoreactive T cells flee from the thymic negative selection due to absence of self-antigen
manifestation in the thymus (Ohashi 2003). The splice variants of self-proteins which do
not have the proper T-cell epitope avoid the thymic deletion (Klein, Klugmann et al.
2000). Moreover, it was suggested that autoimmunity could be induced from mutations in
self-proteins making them immunogenic (Houghton and Guevara-Patino 2004)
(Engelhorn, Guevara-Patino et al. 2006) as seen in mutated pigment-related proteins
associated to melanoma

showed autoimmune T-cell response to this self-

antigen(Engelhorn, Guevara-Patino et al. 2006; Guevara-Patino, Engelhorn et al. 2006).

1.1.6. Major Histocompatibility Complex (MHC)
Whereas nearly all nucleated cells comprise MHC Class I molecules, MHC class
II molecules are located outer surface of antigen presenting cells (APCs); dendritic cells,
macrophages, B cells and a few other types. T cell receptors (TCR) are antigen-specific
receptors that define the specificity T cells. T-cells recognize the peptides presented
through the MHC molecule on the surface of APCs (Babbitt, Allen et al. 1985;
Townsend, Rothbard et al. 1986). Major histocompatibility complex (MHC) class I
molecules present the peptides from the proteolytic degradation of

inside antigens

including viruses and intracellular bacteria, introduce antigens to antigen-specific CD8+
cytotoxic T lymphocytes, whereas MHC class II molecules that are presented on the
surface of antigen presenting cells inrtoduce the antigenic peptides from extracellular and
soluble antigens to the CD4+ T cells, leading activation, proliferation and differentiation
of T cells subsets (McHeyzer-Williams, Altman et al. 1996; Zhu, Cote-Sierra et al. 2003).
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The strong association of MHC class II molecule alleles with diseases lead them
to become the most important genetic risk factors for autoimmune diseases (Jones,
Fugger et al. 2006) such as human leukocyte antigen (HLA) DR4 in insulin depended
diabetes and HLA DR2 haplotype linkage in Multiple Sclerosis(Kent, Chen et al. 2005;
Sospedra and Martin 2005). The link of HLA-B27 with ankylosing spondylitis is another
example of genetically mediated autoimmune disease (Thomas and Brown 2010).

1.1.7. T Cells
T cells are white blood cells well-known as lymphocytes, they mediate cellular
immunity. T cells are differentiated from other cells by T cell receptor (TCR) on their cell
surface. CD4 T cells have two different subtypes; Th1 and Th2. The differentiation of
Th1 and Th2 response is based on cytokine expressions. While Th1 response generates
IL-2 and Interferon gamma (IFN-γ), Th2 response secrete IL-4, IL-5, IL-6, IL-9, IL-10,
and IL-13(Romagnani 1995). CD8 T cells also have different subsets corresponding to
different cytokine expressions; Tc1 subsets produce IFN-γ but not IL-4 or IL-5, Tc0
produce IL-4, IFN-γ and other cytokines, Tc2 subsets produce IL-4 but not IFN-γ (Croft
1994; Sad, Marcotte et al. 1995; MacAry, Holmes et al. 1998; Vukmanovic-Stejic, Vyas
et al. 2000). IL-12 stimulate Tc1 subsets CD8 T cell proliferation, while IL-4 inhibits
proliferation of clones (Vukmanovic-Stejic, Vyas et al. 2000). IL-4 producing CD8 T
cell clones were shown in some diseases such as HIV(Maggi, Giudizi et al.
1994),cutaneous

leishmaniasis

(Uyemura,

Pirmez

et

al.

1993),

lepromatous

leprosy(Salgame, Abrams et al. 1991), periodontitis(Wassenaar, Reinhardus et al. 1996),
and in asthma(Till, Li et al. 1995).
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1.1.8. T helper cells
Naive T-cells is called Th0 cells which facilitate moderate effect, relying on the
ratio of Th1/Th2 cytokines. Th3 is another T cell subset that produces TGF-β(Chen,
Kuchroo et al. 1994) named regulatory T cells(Treg) having Foxp3(Fontenot, Gavin et al.
2003; Carrier, Yuan et al. 2007).TGF-β mediates the differentiation of Foxp3 negative
naive CD4 T cells into Foxp3 positive CD4 T cells called Treg cells(Chen, Jin et al.
2003).
Th1 cells play role in the pathogenesis of Hashimoto’s disease, type 1 DM,
autoimmune gastritis and MS (Romagnani 1997; Romagnani, Parronchi et al. 1997). IFNγ secreted by Th1 cells is vital to macrophage activation in terms of elevating the
microbicidial response (Suzuki and Remington 1988). IL-2 production by Th1 cells is
important for CD4 T cell memory (Darrah, Patel et al. 2007). IFN-γ induces Th1 subset
differentiation (Lighvani, Frucht et al. 2001) through the stimulation of Stat-1 and T-bet
(Szabo, Kim et al. 2000). After the T cell activation through the TCR interaction with
APCs, bulk amount of IL-12 is expressed by APCs. Stat4 augments the Th1 response
through IL-12 mediated phosphorylation transduction leading T-bet activation of IFN-γ
(Kaplan, Sun et al. 1996; Thierfelder, van Deursen et al. 1996).
Th2 subset differentiation is promoted by IL-4. Stat 6 is necessary for inducing
response to IL-4 and Th2 differentiation (Kaplan, Sun et al. 1996). Additionally, Stat 6
activation leads the expression of GATA-3 which is Th2 chief regulatory gene (Jankovic,
Kullberg et al. 2000; Zhu, Guo et al. 2001). GATA-3 is important for the production of
IL-5 and IL-13(Zhu, Min et al. 2004; Zhu, Yamane et al. 2006).The IL-2- induced stat5
activation and IL-4 mediated GATA-3 stimulation through stat6 leading complete Th2
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differentiation(Yamane, Zhu et al. 2005; Zhu, Yamane et al. 2006). Th1 cells are pivotal
for immune defense to pathogens inside the cells, whereas Th2 cells are for immune
defense to extracellular pathogens such as helmints (Mosmann and Coffman 1989; Paul
and Seder 1994).The balance between Th1 and Th2 determines the severity of
autoimmune disease; While Th1 cells are considered as developer pathogenic effect, Th2
cells considered as having inhibitory effects (Nicholson and Kuchroo 1996).
The Th17 cells have been associated with different diseases. Th17 cells are
promoted from naive T cells through inducing TGF-β and IL-6 (Bettelli, Carrier et al.
2006; Veldhoen, Hocking et al. 2006). The function of IL-17 was documented in human
autoimmune diseases such as multiple sclerosis (Matusevicius, Kivisakk et al. 1999),
rheumatoid arthritis(Aarvak, Chabaud et al. 1999), psoriasis (Teunissen, Koomen et al.
1998), tissue inflammation (Steinman 2007). Th17 cells generate IL-17A, IL-17F, IL-21,
IL-22, and have been shown to transfer EAE to naïve recipient (Langrish, Chen et al.
2005) and also Th17 cells induce EAE (O'Connor, Prendergast et al. 2008). It was shown
that IL-23 is the major contributor in induction of EAE along with IL-17(Harrington,
Hatton et al. 2005; Park, Li et al. 2005) and promotes naïve CD4+ T cells into Th17
lineage by inhibiting T-bet and Foxp3 (Mus, Cornelissen et al. 2010).
CD4 Th1 and Th17 T cells are primary mediators of autoimmune diabetes
(Haskins 2005) (Wagner, Newell et al. 1999; Emamaullee, Davis et al. 2009). It was
shown that the levels of Th17-associated proinflammatory cytokines such as IL-1β, IL-6
and IL-23, were increased in NOD mice, insulin-dependent diabetes (Type 1DM) and
IFN-γ induced by IL-12 application stop diabetes development via blocking the IL-17
expression(Zhang, Huang et al. 2012).Th17 cells have been shown to be more effective
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than Th1 cells in disease progress (Langrish, Chen et al. 2005). Moreover, the changed
balance between Th1 and Th17 cells in circulation was considered as a sign showing the
impairment in murine acute Graft-Versus-Host Disease (GVHD) (Pan, Zeng et al. 2012).
Additionally another subset of T cells has been defined called Th9 cell which are
formed after induction with TGF-β and IL-4 and produce IL-9 and IL-10(Dardalhon,
Awasthi et al. 2008; Veldhoen, Uyttenhove et al. 2008; Lin, Chen et al. 2012). It was
shown that Th9 cells can mediate tissue inflammation in a colitis model (Dardalhon,
Awasthi et al. 2008) and in EAE upon adoptive transfer with Th9 cells from myelin
oligodendrocyte glycoprotein (MOG)-specific TCR transgenic T cells (Jager, Dardalhon
et al. 2009).

1.1.9. Trimolecular Complex
For the full T cell Activation APC s are required to present peptides through
MHC molecules to TCR of T cells, however this interaction is weak and some costimulatory signals such as CD28/B7-1(CD80) and B7-2(CD86), 4-1BB/4-1BBL and
adhesion structures (Sharpe and Abbas 2006) CD4/MHC-class II or CD8/MHC class I,
LFA-1/ICAM-1, CD2/LFA-3 , CD40/CD40L are contributed this trimolecular complex
and these interactions generate signal and fully activation of T cells along with cytokines
production(Smith, Graham et al. 1994; Wingren, Parra et al. 1995; Perrin, Scott et al.
1996; Shuford, Klussman et al. 1997). Moreover, co-stimulatory signals through
OX40/OX40L and CD27/CD70 enrich T cell activation in along with CD28/B7 (Croft
2003).
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1.2. INTERSTITAIL CYSTITIS/PAINFUL BLADDER
SYNDROME(IC/PBS)
According to The International Continence Society (ICS), the definition for
IC/PBS is
"the complaint of suprapubic pain related to bladder filling, accompanied
by other symptoms such as increased daytime and night-time frequency, in
the absence of proven urinary infection or other obvious
pathology"(Abrams, Cardozo et al. 2002).
IC is a chronic germ-free inflammation of the urinary bladder with the nonappearance of
verified infection (Forrest and Vo 2001; Bogart, Berry et al. 2007), and is presented by
the symptoms of frequent and urgent urination a long with pain or irritation in the bladder
and lower urinary tract (LUT), necessitating the adding of the new terminology painful
bladder syndrome (PBS)(Toft and Nordling 2006; Hanno 2008) (Bogart, Berry et al.
2007). The prevalence of IC/PBS had been estimated as 55 per 100,000 or 45 per 100,000
by using the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
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criteria(Curhan, Speizer et al. 1999; Clemens, Meenan et al. 2005). IC occurs mainly in
female group with a ratio of 5:1 to male(Bogart, Berry et al. 2007). Based on the high
sensitivity and specificity criteria it was anticipated that nearly 3.5 to 8 million women at
age 18 or older suffer from bladder pain syndrome/interstitial cystitis symptoms in the
United States (Berry, Elliott et al. 2011). According to the NIDDK diagnostic criteria
IC/PBS occurs 17 times more in the relatives of IC/PBS patients than general population
(Warren, Jackson et al. 2004).
The medical costs are predicted to surpass the $100 million per year(Nickel
2004). The diagnostic standard criteria for IC/PBS is compose of presence Hunner’s ulcer
on cystoscopy with urinary symptoms of pelvic pain, urgent to urinate, frequent urination
and ease of dyspareunia after voiding(Hanno, Levin et al. 1990). While the only 20% of
patients present Hunner’s ulcer, 80% of patients do not have ulcer in their bladder
(Messing and Stamey 1978; Koziol 1994). Patients suffer considerable morbidity over the
course of their lives, especially during the most productive years. Advancement in
addressing this disease has been painfully slow due to a lack of understanding of the
underlying pathophysiology.

1.2.1. Etiology of IC/PBS
The etiopathogenesis of IC/PBS has not been explicated yet. Several different
theories have been proposed on the underlying pathology of IC/PBS(Oberpenning, van
Ophoven et al. 2002); defects of bladder barrier glycosaminoglycan(GAG) layer,
infection induced, mast cell activation(Hofmeister, He et al. 1997; Parsons 2003;
Theoharides 2004) autoimmunity, antiproliferative factor(Keay, Zhang et al. 2001),
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decreased sialylation and

glycosylation of

Tam Horsfall Protein(THP)(Argade,

Vanichsarn et al. 2009), TNF-related apoptosis-inducing ligand(TRAIL) and its
receptor(Kutlu, Akkaya et al. 2010), elevated transient receptor potential subtype 1
vaniloid receptor in nerve fibers(Mukerji, Yiangou et al. 2006), neuroendocrine and
neuroimmune mechanisms(Butrick 2003).

1.2.2. Pathological Changes in IC/PBS
IC/PBS is chronic urinary bladder inflammation with the manifested symptoms of
pelvic pain, frequency, urgency, nocturia, irritative micturition, dyspareunia and sterile
urine (Parsons 1996; Warren, Langenberg et al. 2008). The csytoscopic findings of IC
patients compose of glomerulations which are caused by mechanical and congestive
ruptures of capillaries during hydrodistention (Johansson and Fall 1990; Tamaki, Saito et
al. 2004)(MASAHIRO TAMAKI, 2004; Johansson SL, 1990) and Hunner’s ulcers.

1.3. IC/PBS AND AUTOIMMUNITY
IC/PBS exhibits some characteristic features that can be suggested as the signs
for autoimmune chronic disorder (van de Merwe 2007). These features are; no existence
microorganism in the bladder of IC patients, the higher incidence of disease in the people
with certain HLA type(Christmas and Bottazzo 1992), more frequent in women than in
men and existence of autoantibodies in serum of IC patients(Alarcon-Segovia, AbudMendoza et al. 1984; Ochs 1997; Peeker, Atanasiu et al. 2003),the occurrence of another
autoimmune disease in patients and other family members(Warren, Jackson et al. 2004),
improvement with immunologically affective drugs (Sairanen, Tammela et al. 2005;
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Evans, Moldwin et al. 2011) and immune suppressive agents(Liu, Deyoung et al. 2008).
Anti-NGF monoclonal antibody (Tanezumab) is used for treatment of IC/PBS symptoms
showing improvement in pain, urgency and frequency (Evans, Moldwin et al.
2011).Moreover the induction of disease in naïve hosts after adoptive transfer of
lymphocytes or antibodies(Bullock, Becich et al. 1992), and also observing satisfactory
effects after the treatment of a drug that is effecting the immune response(Kim, Liu et al.
2011).

1.3.1. HLA-Linkage in IC/PBS
The upregulation of HLA-DR and antinuclear antibodies (ANA) were observed in
IC patients samples as the sign of immune response (Jokinen, Oravisto et al. 1973;
Christmas and Bottazzo 1992; Liebert, Wedemeyer et al. 1993). In another study the 36%
of patients with IC showed increased antinuclear antibody (Ochs, Stein et al. 1994). IC
also has been connected with HLA DR6 allele of MHC II as a relative risk factor
(Christmas and Bottazzo 1992; Christmas 1994).

1.3.2. Immune Disorders Associated with IC/PBS
The occurrences of IC/PBS with different diseases give some ideas about the
cause of etiology and potential treatment strategy. The high incidence of IC association
with the nonspecific autoimmune disorders including systemic lupus erythematosis
(SLE), rheumatoid arthritis (RA), thyroiditis, and Sjögren syndrome (SS) has been
shown(Oravisto 1980; Fall 1985; Golstein, Manto et al. 1994; Van De Merwe and
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Arendsen 2000; Peeker, Atanasiu et al. 2003; van de Merwe, Yamada et al. 2003).
Moreover, In a case report the chronic IC was revealed through the superimposing course
from rheumatoid arthritis to lupus (Golstein, Manto et al. 1994). Autoantibodies to SSA/Ro and SS-B/La were revealed in approximately 13% of IC patients (van de Merwe,
Yamada et al. 2003).The antibodies to M3R of bladder in IC patients with Sjögren
Syndrome were suggested leading initial symptoms and later local inflammation (Van De
Merwe and Arendsen 2000). IC patients show different diseases concomitantly such that
allergic diseases, sensitive skin diseases irritable, bowel disease, migraine headaches,
fibromyalgia, vulvodynia and pelvic floor dysfunction were higher in IC/PBS patients
than in normal population (Alagiri, Chottiner et al. 1997; Moldwin 2002; Yamada 2003;
Shorter, Kushner et al. 2006).

1.4. BLADDER AUTOIMMUNITY
1.4.1. Autoantibodies in IC/PBS
The accumulation immunoglobulin (IgG, IgA, and IgM) and complement to
elastic structures of bladder of IC were revealed (Helin, Mattila et al. 1987; Gillespie,
Said et al. 1990). It was reported that nearly 50% of the IC patient exhibit autoantibodies
(Ochs 1997). The high incidence of IC in women with waxing and waning symptoms
along occurrence of infiltrating lymphocytes, antinuclear antibodies, anti-tissue
antibodies, and anti-Tamm-Horsfall antibodies are considered as autoimmune sign in IC
pathogenesis (Mattila and Linder 1984; Said, Van de Velde et al. 1989; Gillespie, Said et
al. 1990; Neal, Dilworth et al. 1991).
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1.4.2. Cellular Immune Abnormalities in IC/PBS
In most of the IC patients’ bladder biopsies the main pathological alterations were
the increased vascularity, lymphocytes infiltration, and mast cells accumulation
(Elbadawi 1997). The elevation of T helper cells, B cell nodules, and plasma cells
deposition in bladder biopsies of IC patients was showed indicating a cell mediated
immune reaction (Harrington, Fall et al. 1990; MacDermott, Miller et al. 1991; Elbadawi
1997). In Interstitial cystitis patients’ bladder biopsies the IgG accumulation,
lymphocytes, mast cells and plasma cells infiltration were observed (Boye, Morse et al.
1979; Rosin, Griffiths et al. 1979). In IC patients, the accumulation of CD8+ T cells in
urothelium and CD4+ T cells in lamina propria were demonstrated in bladder biopsies
(Harrington, Fall et al. 1990; Christmas 1994). In some IC patients the massive
accumulation of plasma cells in bladder mucosa and increased perinuclear antineutrophil
cytoplasmic antibodies (p-ANCA) was observed (Thaxton, Eggener et al. 2004; Pacella,
Varca et al. 2010).
The role of autoreactive CD4+ T cells in induction of bladder autoimmune
inflammation was shown in transgenic a URO-OVA mouse which is a model self-antigen
producing ovalbumin in the bladder surface epithelium, derived by UPK2 gene
promoter(Liu, Deyoung et al. 2008; Liu, Chen et al. 2011). The preactivated OVAspecific CD4+ T cells induce autoimmune inflammation in the bladder of this mice and
CD8+ T cell-lacking URO-OVA mice (Liu, Chen et al. 2011).
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1.5. ANIMAL MODELS FOR IC/PBS
Numerous cystitis animal models have been generated in different ways such as
through intravesical administration of immune stimulants, systemic and environmentally
impelled inflammation, immunization with bladder homogenate, transgenic URO-OVA
mice, and naturally occurring models.

1.5.1. EAC Induced by Immunization with Bladder Homogenate
In different mice strains such as BALB/cAN, C3H/HEN, and C57BL/6,
experimental autoimmune cystitis(EAC) animal model were generated with bladder
homogenate and showed the some physiopathological features of cystitis (Bullock,
Becich et al. 1992; Phull, Salkini et al. 2007). The initial experimental autoimmune
cystitis was developed in BALB/cAN mice immunized with a syngeneic bladder
homogenate that induced cell mediated autoimmunity after adoptive transfer of spleen
cells from immunized mice into naïve host(Bullock, Becich et al. 1992). The edema,
fibrosis, perivascular lymphocytic infiltrations and also the deposition of mast cell in
detrusor muscle of bladder were demonstrated in this bladder homogenate induced
cystitis model (Bullock, Becich et al. 1992).
Bladder homogenate obtained from syngeneic animal in Complete Freund’s
adjuvant was used to induce experimental autoimmune cystitis in Lewis rats,
demonstrating urinary frequency, mast cell accumulation and vascular congestion (LuberNarod, Austin-Ritchie et al. 1996). In another study SWXJ mice that are prone to the
generation of autoimmune diseases were immunized with bladder homogenate and

17

developed experimental autoimmune cystitis showing the symptoms of increase urination
frequency and decrease micturition volume along with histopatlogical alterations such as
increased leukocytes infiltration, mast cell infiltration and thickened lamina propria (Lin,
Liu et al. 2008).
Moreover, in guinea pig models, which were sensitized to Ovalbumin (OVA),
developed experimental cystitis demonstrating mast cell infiltration after administration
of Ovalbumin antigen into bladder (Saban, Christensen et al. 1991). In another parallel
study in mice showed that Ovalbumin instillation transurethrally developed experimental
cystitis, on the other hand mast cell deficient mice did not developed bladder
inflammation (Saban, Saban et al. 2001). It was suggested that T helper cells could play a
role in immune response in the bladder of antigen induced cystitis (Ratliff, Klutke et al.
1994; Ratliff, Klutke et al. 1995).

1.5.2. Naturally Occurring Cat Model for IC/PBS
Feline model of IC showed the similar symptoms of IC/PBS such as increase
urinary frequency and pain (Buffington, Chew et al. 1997). The lesser urinary excretion
of GP-51 glycosaminoglycan, increased bladder wall permeability, elevated substance P
immunoreactivity and neurokinin-1 receptors in this model were observed (Gao,
Buffington et al. 1994; Caito and Masty 1995; Press SM 1995; Buffington and Wolfe
1998; Moldwin 2002). The major advantage of this cat model is generation with the
absence of external stimulants. The restriction of this model is dissimilar gender
distribution in cats compared to human; in human more than 90% of IC is women, in cats
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about half to half distribution (Pontari MA 1995). And also the etiology of cystitis
development on this cat model is unknown. Other issues are such as handling problems
that require veterinarian involvement, and cost highly expensive handling this animal in
animal facilities (Westropp and Buffington 2002).

1.5.3. Intravesical Irritant Instillation Models
Urine of IC patients instillated into bladder of rabbits to test the histological and
functional changes (Kohn, Filer-Maerten et al. 1998), intravesical acetone applied to
induce IC in rats, monkeys, and rabbits (Kato, Kitada et al. 1990; Ghoniem, Shaaban et
al. 1995; Shimizu, Kawashima et al. 1999). Moreover, intravesical acid administration
showed increase neutrophil accumulation and edema(Elgebaly, Allam et al. 1992). An
antineoplastic drug -Cyclophosphamide is mostly used for induction of cystitis in
animals. It damages the urothelium, mucosa, and causes edema, leukocytes accumulation
in bladder tissue and hemorrhage (Locher and Cooper 1970; Cox and Abel 1979; LanteriMinet, Bon et al. 1995). Mustard oil administration intravesically and electrical
stimulation of pelvic ganglia were studied to test to bladder distension in regard to
afferent fibers in visceral pain (Koltzenburg and McMahon 1986). Instillation of Xylene,
lipopolysaccharide (LPS), and polyinosinic-polycytidilic acid incited inflammation in rat
bladder (Luber-Narod, Austin-Ritchie et al. 1996).

1.5.4. EAC Induced by Immunization with Recombinant mUPK2 Protein
The immune response to self-antigen mediated

organ specific autoimmune

diseases EAC model was generated by targeting uroplakins with recombinant rmUPK2
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protein(Altuntas, Daneshgari et al. 2011). Bladder specific protein UPK2 was used to
immunize the mice and assessed bladder urodynamic, showing the symptoms of increase
urination frequency and decrease micturition volume along with increased T cell
infiltration in the bladder.

1.5.5. URO-OVA Mice
EAC model with URO-OVA mice (produce a membrane structure of the Ag
Ovalbumin(OVA) like a self-antigen on the urothelium deriven by Uroplakin II gene
promoter) formed

autoimmune cystitis through OVA-specific OT-I CD8+ T-cells;

however OVA is not endogenous antigen of bladder and also the bladder urodynamic
changes and pain correlated to IC/PBS phenotype have not been characterized (Liu,
Evanoff et al. 2007; Liu, Deyoung et al. 2008).

1.5.6. Immune Stimulant Induced Cystitis Models
The bacterial product of LPS administration intravesically resulted into cystitis
showing neutrophil invasion, hemorrhage and edema (Jerde, Bjorling et al. 2000).
Neurokinin-1 knockout mice did not show inflammation and edema after instillation of
dinitropheny14-ovalbumin even the existing of high mast cells (Saban, Saban et al.
2000). In mast cell knockout mice, the intravenous administration of substance P or LPS
incited cystitis in these mice (Bjorling, Jerde et al. 1999). In another study, the tail-side
muscle injection of pseudorabies virus revealed bladder inflammation in rats (Jasmin,
Janni et al. 1998).In mice model of cystitis with pseudorabies virus (PRV) injected, the
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mast cell infiltration in lamina propria led by necrosis factor alpha (TNF) along with
pelvic pain mediated by histamine have been demonstrated(Rudick, Schaeffer et al. 2008;
Rudick, Schaeffer et al. 2009). In addition, the Cathelicidin (LL-37) an antimicrobial
peptide were used to generate bladder inflammation in mice (Oottamasathien, Jia et al.
2011).

1.5.7. Noxious Environmental Stimulus Induced Cystitis Animal Models
Environmental stimulus induced cystitis animal model has been reported by
administration of physical and physchological stress factors in such studies that restraint
stress induced mast activation in bladder(Spanos, Pang et al. 1997), applied acute cold
stress induced edema, leukocyte invasion, and mast cell degranulation

in rat

bladder(Ercan, San et al. 1999). In another study, it was shown the temperature mediated
bladder pathological changes such as distraction of tight junctions, desquamation and
damages of subapical vesicles that are alike observed in IC patients(Jezernik, Medalia et
al. 1995; Elbadawi 1997; Lavelle, Meyers et al. 2000).

1.6. UROEPITHELIUM
It was suggested that painful bladder syndrome occurs due to some modification
on uroepithelium in IC. Urothelium, which have three cell layer containing basal cells,
intermediate and umbrella cells, forms the inner surface of urinary bladder providing a
barrier against urine and other metabolites (Khandelwal, Abraham et al. 2009).The tight
junctions in balder urothelium support the resistance of cells (Lewis and Kleine
2000).The defect of urothelial barrier such as damaging of tight junctions, umbrellas
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cells, cell adhesions which are mostly observed in IC/PBS patients’ bladder, could allow
urine, noxious elements and chemical metabolites to invade into underneath layers of
tissue and causing the symptoms of frequent o urinate, urgent to urinate and pelvic pain
(Birder 2011; Birder, Hanna-Mitchell et al. 2011). Urothelium is in a web of interaction
with immune and inflammatory cells along with bladder nerves, smooth muscle,
urothelial cells and afferent nerves exist closer to the uroepithelium that could be
stimulated by substances secreted by urothelium cells and bladder nerves(Birder and de
Groat 2007; Birder 2011).

1.7. UROPLAKINS
The mammalian Uroplakins comprising human, bovine and mouse, are highly
conserved (Wu, Lin et al. 1994). Where UPII and UPIII contain a single transmembrane
domain(Sun 2006) , UPIa and UPIb have four trans membrane domain (Levy and
Shoham 2005). It is suggesting that Uroplakins take a part as a protective role for the
Asymmetric Unit Membrane (AUM) from breaching during bladder expansion (Born,
Pahner et al. 2003; Kong, Deng et al. 2004) . AUM particles consist of five Uroplakins
(UPs), which are tetraspan structured UPIa and UPIb and single spanned UPII, UPIIIa,
and UPIIIb proteins, are generated specifically in the urothelium except UPIb that is also
expressed in the eye and reside in the umbrella cell layer (Wu, Medina et al. 1995; Deng,
Liang et al. 2002). UPIa (27 kDa), UPIb (28 kDa), UPII (15kDa) and UPIIIa (47 kDa)
are integral membrane proteins of urothelial plaques (Yu, Lin et al. 1994). The
heterodimerization of UPII with UPIa and heterodimerization of UPIIIa or UPIIIb with
UPIb are pivotal for transferring from endoplasmic reticulum to the cell surface (Wu,
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Medina et al. 1995; Deng, Liang et al. 2002; Tu, Sun et al. 2002). The existences of the
uroplakins in bladder are well chosen target for the establishment of EAC.

1.7.1. Function of Uroplakins
Uroplakins possess different function in bladder such as contributing the barrier
formation of apical membrane (Hu, Meyers et al. 2002), mediating bladder function
alteration (Aboushwareb, Zhou et al. 2009) and cell signaling (Hasan, Ou et al. 2007;
Thumbikat, Berry et al. 2009). Uroplakins (Ia, Ib) have substantial roles in immunologic
signaling, infection, membrane structure, cell migration (Hemler 2003; Levy and Shoham
2005). The urodynamic with cystometry (CMG) studies on Uroplakin II and IIIa
knockout mice showed significant bladder function alteration including increased
nonvoiding contractions, the pressure between micturitions, remaining volume after
voiding(Aboushwareb, Zho et al. 2007; Aboushwareb, Zhou et al. 2009). UPs are
expressed mostly in urothelial tissues and are detected in the urothelial originated
carcinomas more than 50% (Wu, Osman et al. 1998; Huang, Shariat et al. 2007).

1.7.2. UPIIIa and Plaques
The apical surface of umbrella cells comprise hinges and plaques which form the
scalloped appearance and plaques containing nearly 3000 AUM particles cover the more
than 80% of umbrella cell surface(Kachar, Liang et al. 1999; Apodaca 2004). It was
suggested that urothelial plaques could provide the sustainability of urothelium
permeability barrier along with the apical membrane of umbrella cells and UPIIIa
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knockout mice revealed a small number of plaques (Hu, Deng et al. 2000). And also the
UPII deficiency caused totally absence of urothelial plaques (Kong, Deng et al. 2004).
The role of UPIIIa on permeability of apical membranes of umbrella cells was
tested on UPIIIa knockout mice showing the increased permeability to water and urea,
increase urothelial leakage through the umbrella cell layer (Hu, Deng et al. 2000; Hu,
Meyers et al. 2002). IC/PBS commonly demonstrates the increase of bladder urothelium
permeability (Parsons 2007). Moreover the diminished UPIIIa manifestation led
hyperplastic uroepithelium, expanded ureters and vesicoureteral reflux (Hu, Deng et al.
2000). It was suggested that UPIIIa containing large cytoplasmic domain interrelates with
cytoskeleton and these cooperation might stabilize membrane domains in umbrella cells
(Hu, Deng et al. 2000; Apodaca 2004).

1.8. BIOMARKER FOR IC/PBS
The possible biomarkers that are suggested for IC are the urine Antiproliferative factor
(APF),Heparin-Binding EGF-like Growth Factor (HB-EGF), Epidermal Growth Factor
(EGF), IL-6 and Insulin Like Growth Factor Binding Protein-3(IGFBP3) (Erickson, Xie
et al. 2002). Antiproliferative factor(APF), which is produced by urothelium of IC/PBS
patients, showed the inhibitory effect on bladder cell proliferation and causing failure of
damaged bladder tissues(Keay, Szekely et al. 2004; Hanno 2007).
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CHAPTER II
METHODS

2.1. Peptide
We employed an online database (http://www.syfpeithi.de/) (Hans-Georg
Rammensee 1999) research of MHC and their recognized peptide motifs to predict
potentially immunogenic peptides of known sequences for bladder-specific
Uroplakins. The amino acid sequences of all three Uroplakins (Ia, Ib II, IIIa-b) were
placed in online T- cell epitope, and MHC motif prediction program to figure out
possible immunogenic peptide MHC motif sequence for each different mice
strains(C57BL/6-H2 b, BALB/c-H2 d, C3H-H2 k).
For the SWXJ mice, the peptides derived from the known sequences of
Uroplakins were chosen based on having the -KXXS- tetrapeptide-binding motif for IAs
and IAq MHC class II molecules expressed in this mouse (Table 1). We identified that
UPK3A 65-84, 20-mer peptide derived from the mouse bladder specific Uroplakin 3A
protein, contain -SXXVXV- binding motif for IAd MHC class II molecules expressed in
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BALB/c mice was predicted the uppermost immunogenic according to online database.
UPK3A 65-84 peptide, derived from the sequences of mouse bladder specific Uroplakin
3A protein and other peptides for SWXJ mice were synthesized and purified by the
Molecular Biotechnology Core Facility of the Lerner Research Institute, Cleveland Clinic
Foundation, Cleveland, OHIO. The standard solid phase approach and FMOC side chainprotected amino acids were used to synthesize the peptides. The peptides were purified
>97% with Reverse Phase HPLC followed by mass spectrometry to check the amino acid
sequences of peptides.

Table 1.Uroplakin derived peptide sequences and MHC II binding motifs for SWXJ mice
strain and BALB/c mice strain
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2.2. Mice and immunization

BALB/c female mice and SWXJ female mice were purchased from Jackson
Laboratory, and at 6-8 weeks of aged mice were injected subcutaneously (s.c.) in the
abdominal flank with or without 200μg of the peptides (Table 1) in 200 µl of an emulsion
of equal volumes of water and Complete Freund’s Adjuvant (CFA) containing 400 µg of
Mycobacteria tuberculosis H37RA (Difco Laboratories, Detroit, Michigan, USA). All
protocols were pre-approved by the institutional animal care and use committee of the
Case Western Reserve University in compliance with the Public Health Service policy on
humane care and use of laboratory animals.

2.3. Weighting Bladder Tissues
At 5 weeks after immunization the mice and bladder weight were measured. The
ratio of bladder weight/body weight was calculated and compared with control-CFA
immunized group.

2.4. Cell culture and Proliferation Assays

As it described previously (Jane-wit, Yu et al. 2002; Altuntas, Johnson et al.
2006; Altuntas, Daneshgari et al. 2011), to find out the immunogenicity of peptides,
inguinal and axillary lymph node cells (LNCs) were removed from mice at 10 days after
immunization with UPK3A 65-84 or the other peptides. The removed LNCs were placed
on a tissue culture dish and teased them apart into single cell suspension by squashing
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with 3ml syringe plunger through with a cell strainer(nylon mesh) removing the clumps
and debris. The cell suspensions were washed with Hank's Buffered Salt Solution
(HBBS) (Life Technologies, Grand Island, NY) and centrifuged for 10 minutes at 300xg
at 40C. The cell pellets were suspended and the cell count was made to check viability.
The cells were cultured in a way of single-cell suspension in 96-flat-bottom-well
microtiter Falcon plates (BD Biosciences, San Jose, CA, USA) at 3x105 cells/well in
Dulbecco modified Eagle medium (DMEM) (Mediatech CellGro, Herndon, VA, USA)
with 10% fetal bovine serum (HyClone), 5% HEPES buffer, 2% L-glutamine, and 1%
penicillin/streptomycin (Invitrogen Life Technologies) included. And then the peptides
and Ovalbumin (as a control) were added in serial 10-fold dilutions to triplicate wells
with positive control wells containing 2 µg/ml antimouse CD3 (BD Biosciences).

T cell isolation-The CD4+ and CD8+ T cells proliferative response to the
UPK3A 65-84 peptide was determined. CD4+ and CD8+T cells were purified and
isolated from 10-day primed LNC by using anti-CD4- and anti-CD8-coated magnetic
bead sand through a MACS LS column using a Midi MACS cell separator (Miltenyi
Biotec, Auburn, CA, USA). The purified 3x105 cells/well of CD4+ or CD8+ T cells were
cultured with 5 × 105 cells/well gamma-irradiated (2000 rads) syngeneic splenocyte
feeders.50 µg/ml of UPK3A 65-84 peptide or Ovalbumin (control) were inserted into
triplicate cultured wells with positive control wells containing 2 µg/ml antimouse CD3
(BD Biosciences).
All the cultured cells were incubated at 37 °C in humidified air containing 5%
CO2. After 96 hours of culture, wells were pulsed with [methyl-3H] thymidine (l μCi per
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well; specific activity 6.7 Ci/mmol; New England Nuclear, Boston, MA, USA) and
harvested 16 h after pulsing by aspiration onto glass fiber filters. The level of
incorporated radioactivity was determined by scintillation spectrometry. The results are
showed as mean counts per minute (cpm) of triplicate experimental cultures and/or cpm
of cultures with antigen divided by mean cpm of cultures without antigen (stimulation
index; (Jane-wit, Yu et al. 2002).

2.5. Cytokine Analysis

As described in previous studies (Altuntas, Johnson et al. 2006; Altuntas,
Daneshgari et al. 2011); IFN-γ, IL-2, IL-4, IL-5 and IL-10 cytokine concentrations were
determined by ELISA. The measurement was performed on the 48 hour supernatants of
10-day-primed LNC cultured in supplemented DMEM at 5x106 cells/well in 24-well flatbottom Falcon plates (BD Biosciences) in the presence of 25 µg/ml UPK3A 65-84 and
Ovalbumin (as a control) in a final volume of 2.0 ml/well. Purified capture/detection Ab
pairs and recombinant cytokines were obtained commercially (BD Biosciences) and
included anti-mouse IFN-γ (R4-6A2 and biotin XMG1.2), anti-mouse IL-2 (JES6-1A12
and biotin JES6-5H4), anti-mouse IL-4(11B11 and biotin BVD6-24G2), anti-mouse IL-5
(TRFK5 and biotin TRFK4), and anti-mouse IL-10 (JES5-2A5 and biotin SXC-1).
Microtiter plates were coated with anti-cytokine capture mAb (0.5-2µg/ml) in 50 µl PBS
for 6 hours at room temperature (RT). Wells were blocked with 200µl of 3% BSA in PBS
for 2 hours at RT. 100 µl/well from each samples were added and incubated at RT for 4
hours. From the biotinylated anti-cytokine detecting mAb(1-2µg/ml) 100µl were added
after washing steps and incubated at RT for 45 minutes. Following the washing steps
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100µl/well Avidin-peroxidase were incubated 30 minutes at RT. Working substrate
solution, ABTS, was added to all wells for 20-30 minutes and followed by the addition of
stop solution. Absorbance was measured at 405 nm using a model Versamax ELISA
microplate reader (Molecular Devices, CA). Standard values were plotted as absorbance
vs cytokine concentration, and sample cytokine concentrations were determined as values
within the linear part of the standard curve established using known concentrations of
each cytokine.

2.6. Total Antibody Titer

The total antibody titer was determined by enzyme-linked immunosorbent assay
(ELISA) in sera. 5 week after immunization the serum samples were obtained from the
each immunized mice with UPK3A 65-84 and from Ovalbumin injected mice. After the
coating the microwell plate with peptide antigens, the different serial dilutions (1/200,
1/400, 1/800, 1/1600, 1/3200, 1/6400, 1/12800, 1/25600) of serum samples of each mice
(n=5) were used. The goat-anti-mouse antibody IgG (H+L)-HRP (Horseradish
Peroxidase) conjugated (1/8000) (Southern Biotech) was used. The plates were read by
ELISA reader at 405 nm.

2.7. Isotype-Specific Antibody Titers

As described in (Altuntas, Johnson et al. 2006; Altuntas, Daneshgari et al. 2011),
Isotype-specific antibody titers to UPK3A 65-84 was determined in the serum samples of
immunized mice 5 week after immunization, according to the manufacturer’s instructions
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using the mouse Mono AB ID/SP ELISA kit (Zymed, Invitrogen, Carlsbad, CA, USA).
In brief, UPK3A 65-84-antigen (10µg/ml) in 50µl PBS coated the microtiter plates and
incubated at 40C overnight. Wells were blocked with 1% of BSA in PBS for 1 hour at
370C after washing. The serum samples (n=4) were serially diluted and 50µl of sera was
added to each well and incubated for 30 minutes at 370C. The biotinylated antibodies
specific to each mouse antibody isotypes (IgG1, IgG2a, IgG2b, IgG3) in 50µl PBS were
added and incubated for 30 minutes at 370C, and followed by addition of horse radish
peroxidase (HRP)-streptavidin (50µl/well, 30 minutes at 370C) and substrate solution
ABTS ((2, 2’-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt)
administration and then the absorbance was measured at 405 nm by ELISA reader.

2.8. Real Time-PCR
The inflammatory genes(IFN-γ, TNF-α, IL-1β, IL-17A) expression levels was
performed

5 weeks after immunization in the bladders of immunized and control

mice(CFA injected group and Naïve mice) comparing with the kidney, ovary, uterus, and
liver. Total RNA was extracted from bladder of EAC mice and controls and then
converted to cDNA for gene expressions analysis. RNAs were extracted from bladders
following Invitrogen TRIzol protocol (Invitrogen). cDNAs were synthesized with
Invitrogen Super Script III cDNA Synthesis Kit. The primers were designed with online
Universal Probe Library Assay Design Center of Roche. qRT- PCR using the Sybr
Green PCR Master kit (AB, USA) with ABI Prism 7500 Sequence Detection System was
conducted

using

the

following

primer

pairs:

interferon

(IFN)

γ,

sense,

TGATGGCCTGATTGTCTTTCAA, antisense, GGATATCTGGAGGAACTGGCAA;
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tumor necrosis factor (TNF) α, sense, CAAAGGGAGAGTGGTCAGGT, antisense,
ATTGCACCTCAGGGAAGAGT;

interleukin

(IL)

1β,

sense,

GAGTGTGGATCCCAAGCAAT, antisense, AGACAGGCTTGTGCTCTGCT; IL-17A,
sense, TCCACCGCAATGAAGAC, antisense, CTTTCCCTCCGCATTGAC; β-actin,
sense, GGTCATCACTATTGGCAACG, antisense, ACGGATGTCAACGTCACACT.
The quantitation of gene expression levels were calculated with comparative Ct method.
The Ct values of the samples from immunized mice and the control mice are normalized
to endogenous housekeeping gene, β-Actin.

2.9. Histologic Analysis

Mice were sacrificed and bladders weighed. The bladder was sectioned at the
equatorial midline and fixed in 10% neutral formalin. After fixation, the tissues were
dehydrated and embedded in paraffin. Serial 5-µm cut tissue sections were placed on
microscope slides, dewaxed, and rehydrated for routine hematoxylin and eosin staining.
Gross histologic observations were performed using light microscopy (Olympus DP70
digital microscope).

2.10.

Immunocytochemistry

Immunostaining was performed as described in Altuntas et al., 2006(Altuntas,
Johnson et al. 2006). Briefly, unmasked in 1 mM EDTA and blocked formalin-fixed
paraffin-embedded 5-µm tissues sections were treated with a 1:250 dilution of rat
antimouse CD3 (Novacastra, Newcastle Upon Tyne, UK) followed by a 1:100 dilution of
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mouse-adsorbed

biotinylated

goat

anti

rat

immunoglobulin

(IgG)

(BD

Biosciences).Slides were treated with 1.5% H2O2 in methanol and then the slides were
developed conventionally using streptavidin-horseradish peroxidase complex (ABC kit;
Vector Laboratories, Burlingame, CA, USA), 3, 3’- diaminobenzidine chromogen
solution and H2O2 substrate (Biognex, San Ramon, CA, USA). The slides were stained
with H&E and dehydrated in an ascending gradient of ethanol followed by xylene. The
slides were examined by light microscopy (Olympus DP70 digital microscope).

2.11.

Urinary Frequency-Volume Assessment (FVC)

Twenty four hr earlier to FVC assessment, solid food was eliminated from cages
and supplied with lactose-free milk to minimize the frequency and mass of the feces
produced at the time of examination(Liu and Daneshgari 2006). 24-hr micturition and
sipping behaviors of mice were measured by placing each mouse individually in
metabolic cages (MED-CYT-M; Med-Associates, St. Albans, VT). Urine was collected
in a plastic tray located on an analytical balance (VI- 3 mg; Acculab, Huntingdon Valley,
PA) set directly underneath of each cage. Balances were linked to a data acquisition
software program advanced by manufacturer, which measure the weight of urine
collection along the defined period of time. Throughout testing, mice were provided with
free access to lactose-free milk and water, and the testing room was maintained on a
light/dark cycle alike usual housing environments. At end of testing, milk and water
bottles were examined to quantity consumption of fluid over the 24 hr period. The data is
analyzed with OriginLab Data Analysis and Graphic Software.
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2.12.

Pain Assessment

We assessed the pelvic pain response of mice by using calibrated von Frey
monofilaments after the 5 weeks of immunization and after adoptive of CD4+ T cells,
CD8+ T cells, serum, and B cells at day 5, 10, 20, 30. We tested pelvic pain by using
quantitative behavior testing methods to assess tactile sensitivity of pelvic region
(Rudick, Schaeffer et al. 2008; Rudick, Schaeffer et al. 2009).The von Frey filaments
applied to the pelvic region of the BALB/c mice. The withdrawal frequency was
calculated in percentage out of 10 times pocked mice with each of the von Frey filaments.
The measurement was assessed with 12 von Frey hairs using the sizes 1.65, 2.36, 2.44,
2.83, 3.22, 3.61, 3.84, 4.08, 4.17, 4.31, 4.56, 4.74 with the forces (gr) 0.008, 0.02, 0.04,
0.07, 0.16 0.4, 0.6, 1, 1.4, 2, 4, 6 respectively. The each of the filaments was employed
for 1-3 second in an order beginning from the thinner to thicker with a 5-8 second
intervals between two stimuli, completing to 10 times pocking.

2.13.

Adoptive Transfer of EAC

To determine whether EAC (transferring the immunologic functionality and
features into naïve host) could be transferred into naïve BALB/c mice, the isolated and
activated CD4+ T cells, CD8+ T cells, B-Cells and also collected Sera from immunize
groups were used. 6- to 8-week-old BALB/c female mice were immunized s.c. in the
abdominal flank on day 0 with either 200 μg Ovalbumin (OVA; Sigma) or 200 μg
UPK3A 65-84 in 200 μl of an emulsion of equal volumes of water and Freund’s adjuvant
(Difco)and 400 μg Mycobacteria tuberculosis H37RA (Difco, Detroit, Michigan).
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Ovalbumin was used as a control. Lymph node cells were taken at day 8-10 after
immunization and LNCs were stimulated with immunogens (50 µg/ml) in vitro for 96
hours, and the isolated and purified 2x107 CD4+ or CD8+ T cells by magnetic bead
separation were transferred into naive mice by i.v tail vein injection (2x10 7 cells in PBS,
200 μl per mice/naïve recipient) and the development of EAC phenotype was assessed by
measuring micturition frequency by FVC at day 20, and referred pelvic pain by von Frey
Filaments at day 5, 10, 20, 30. Correspondingly, B-Cells were isolated from spleens of
immunized mice 5 weeks after injection with peptides (UPK3A 65-84, or Ovalbumin)
with magnetic bead separation using anti-CD45R (B220) Micro Beads, mouse, (Miltenyi
Biotec). The isolated B-Cells were transferred into syngeneic naïve recipient by i.v. tail
vein injection at 2x107 cells/per mice (2x107 cells in PBS, 200 μl per mice/naïve
recipient). Likewise, serum samples taken from at 5 weeks after immunization with
immunogens (UPK3A 65-84 or Ovalbumin), the collected and pooled sera were injected
(3 injections of 200 μl per mice, i.v, every other day) into naive recipient BALB/c female
hosts for determining their ability to mediate disease.

2.14.

Cystometrogram (CMG)

CMG testing was performed as previously described (Kim, Huang et al. 2007;
Liu, Lin et al. 2010). 5 weeks after immunization mice were put in particular metabolic
cages for 2–4 h. During this time, the PE-10 catheter was attached via a stopcock to both
a pressure transducer and a flow pump. The bladder was then filled with room
temperature saline (1 ml/h) via the catheter, while bladder pressure was recorded. The
animals were conscious and could micturate through the urethra during the study. Urine
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was collected in a beaker on a force transducer (Model PT5, Astro-Med) set underneath
of every cage. The pressure and force transducers were connected to an amplifier, chart
recorder, and a computer for recording data. With CMG data the following measurements
were performed: threshold pressure, peak voiding pressure, resting pressure, compliance,
and mean inter contractile intervals. Peak voiding pressure was described as the highest
pressure throughout micturition. Threshold pressure was the pressure just before the
initial micturition phase. Resting pressure is the pressure right after the micturition.
Compliance was calculated by dividing the voided volume by the variation in bladder
pressure throughout the voiding phase (threshold pressure minus the resting pressure).
The mean intercontractile interval is the time between the start of the one voiding cycle
(initial resting pressure) to the end of that voiding cycle (end of the micturition phase).

2.15.

Statistical analysis

The unpaired Student t-test was used to analyze differences in micturition
frequency, mean urine output/micturition ratio, and bladder weight/body weight ratio
between UPK3A 65-84 and control-immunized mice. For RT-PCR experiments,
statistical analysis was performed using a one-way analysis of variance (ANOVA) with
Tukey’s post hoc test for comparisons between groups. The pain differences between
groups were analyzed by a one-way ANOVA followed by a posthoc test comparison
using Dunnet’s multiple comparisons. A value of p<0.05 was considered statistically
significant.
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CHAPTER III
RESULTS

3.1. Immunogenic Peptides Selection and Prediction Based on MHC motifs

The online database (http://www.syfpeithi.de/) (Hans-Georg Rammensee 1999)
research of MHC and their recognized peptide motifs gave us potentially higly
immunogenic peptides of known sequences of bladder-specific Uroplakins for BALB/c
mice. For the SWXJ mice, peptides were derived from the known sequence of Uroplakins
were selected based on having the -KXXS- tetrapeptide-binding motif for IAs and IAq
MHC class II molecules expressed in SWXJ mice(Table I). The KXXS motif has been
used for immunogenic peptide selection in many studies(Table II) such as experimental
autoimmune encephalomyelitis (EAE) in SWXJ, SWR/J and SJL/J mice(Tuohy and
Thomas 1995; Tuohy, Thomas et al. 1995), experimental autoimmune myocarditis and
autoimmune sensorineural hearing loss in SWXJ mice(Jane-wit, Yu et al. 2002; Solares,
Edling et al. 2004). We identified that UPK3A 65-84, 20-mer peptide derived from the
mouse bladder specific Uroplakin 3A protein, contain -SXXVXV- binding motif for IAd
MHC class II molecules expressed in BALB/c mice was predicted the uppermost
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Immunogenic according to online database and [methyl-3H] thymidine incorporated
proliferation assays.

Immunogenic
Peptide
PLP 104-117

Amino Acid Sequence
-KXXS- Motif
KTTICG -KGLS-ATVT

MOBP 37-51

REIVD-RKYS-ICKSGC

MOG 92-106
CAMHC 406-425

DEGGYTCFF-RDHS-YQ
KVGNEYVT-KGQS-VQQVYYSI

CAMHC 16311650
Coch 131-150

LSQAN-RIAS-EAQKHLKNSQA
STQEATG-RAVS-TAHPPSGKR

β-tectorin 71-90

FVIPDLSP-KNKS-YCGTQSEY

Inα 215-234

FLVAHTRA-RAPS-AGERARRS

Reference
(Tuohy and
Thomas 1995)
(Amor, Groome et
al. 1994)
Holz, Bielekova et
al. 2000)
(Jane-wit, Yu et al.
2002)
(Jane-wit, Yu et al.
2002)
(Solares, Edling et
al. 2004)
(Solares, Edling et
al. 2004)
(Altuntas, Johnson
et al. 2006)

Table 2.Mostly used immunogenic peptides with -KXXS- MHC motif sequences.
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3.2. Immunogenic UPK3A 65-84 Peptide Elicited Proliferative Response in
BALB/c mice.

UPK3A 65-84, 20-mer peptide derived from the mouse bladder specific
Uroplakin 3A protein, contain -SXXVXV- binding motif for IAd MHC class II molecules
expressed in BALB/c mice was predicted highly immunogenic according to online
database (http://www.syfpeithi.de/). The relatively highest immunogenicity of this
peptide among the other peptides was confirmed with [methyl-3H] thymidine
incorporated proliferation assays. Lymph node cells (LNC) taken 10 days after
immunization with UPK3A 65-84 showed antigen specific proliferative responses to
UPK3A 65-84 but were unresponsive to Ovalbumin as a control (Figure 1a-b). UPK3A
65-84 was able to elicit extensive recall proliferative responses whereas the rest of the
peptides were relatively non-immunogenic when assessed through stimulation index or
with cpm.
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UPK3A 65-84(BALB/c)
UPK3A 65-84(SWXJ)
UPK3A 36-55(SWXJ)
UPK3B 132-151(SWXJ)
UPK3B 159-178(SWXJ)
UPK3B 238-257(SWXJ)
UPK2 115-134(SWXJ)
UPK1A 167-186(SWXJ)
OVA(BALB/c)
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Figure 1. UPK3A 65-84 is Higly Immunogenic in BALB/c mice. 20-mer peptide
derived from Uroplakin proteins, contain -SXXVXV- binding motif for IAd MHC class
II molecules expressed in BALB/c mice, and for the SWXJ mice, peptides were derived
from the known sequence of Uroplakins were selected based on having the -KXXStetrapeptide-binding motif for IAs and IAq MHC class II molecules expressed in this
mice. Characterization of the Immune Response to UPK3A 65-84- Lymph node cells
(LNC) taken 10 days after immunization with UPK3A 65-84 and other peptides showed:
(A-B) antigen specific recall proliferative responses to UPK3A 65-84 but not to
Ovalbumin, and other Uroplakin derived peptides (n=5), expressed results are the mean
of triplicate cultures pulsed with [methyl-3H] thymidine graphed based on the stimulation
index (A) and radioactivity in cpm (B).
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3.3. Th1-like Proinflammatory Phenotype was revealed to UPK3A 65-84 in
immunized mice.

ELISA analysis of 48 hour supernatants of cultured and peptide induced LNCs
from 8-10-day after immunization showed that the recall responses to UPK3A 65-84 was
a proinflammatory type-1 cytokine response characterized by enhanced expression of
IFNγ and IL-2 and nearly no production of IL-4, IL-5 and IL-10 (Figure 2).

Cytokine
Figure 2. UPK3A 65-84 Induces a Th1-like Proinflammatory Response. ELISA
analysis of cytokines from the 48-hour supernatant of cultured LNCs demonstrated the
response to UPK3A 65-84, a proinflammatory type-1 phenotype with high production of
IFNγ and IL-2 and low production of IL-4, IL-5 and IL-10 in response to UPK3A 65-84,
(n=8).
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3.4. UPK3A 65-84 Activates CD4+ Proinflammatory Th1-Like T Cells in an
IAd-restricted Manner
UPK3A 65-84 was capable of inducing CD4+ T –cell proliferative response. Its
responsiveness was elicited from purified (>90%) CD4+ T cells and LNC but not CD8+
T cells (Figure 3). CD4+ T cells and CD8+ T cells were purified from whole LNC by
magnetic bead separation and reactivity to UPK3A 65-84 at 50µg/mL was examined in
culture

with

gamma-irradiated

syngeneic

splenocyte

feeders.

The CD4+ enriched T-cells demonstrated enhanced proliferation to UPK3A 65-84
compared to the enriched CD8+ T-cells and LNC at 8-10 days after immunization
(Figure 3). This confirms that UPK3A 65-84 preferentially actuates CD4+T cells
restricted to IAd of MHC class II molecules in BALB/c mice.

3.5. High Titer Antibody Response to UPK3A 65-84 along with Type 1 antibody
isotype was showed in Immunized mice.
All sera collected from mice at 5 weeks after immunization and serially diluted
antibody isotype titers to UPK3A 65-84 were determined. The high titer systemic serum
antibody response to UPK3A 65-84 peptide was observed (1/12,800) (Figure 4). In some
mice immunoreactivity the titer was clearly detectable at dilutions exceeding 1/12,800.
The predominant antibody isotypes to the UPK3A 65-84 peptide were IgG2a and IgG3,
which are known to be induced by IFN-γ, and inhibited by IL-4. This finding indicated
that the response to peptide is Th1-associated Ab response with elevated production of
IgG2a and IgG3, low production of IgG1, and IgG2b (Figure 5).
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Figure 3. CD4+ T cell Reactivity to UPK3A 65-84.The high recall proliferative
response to LNC and from CD4+ T cells, but not CD8+ T cells, purified (>90%) by
magnetic bead separation, (n=5), results are the mean of triplicate, after 96 hour, wells
were pulsed with [methyl-3H] thymidine and harvested 16h later by aspiration onto glass
fiber filters. The incorporated radioactivity was determined with scintillation
spectrometry. All error bars show ±SE.
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Figure 4. High Antibody Response to UPK3A 65-84. ELISA analysis of sera taken 5
weeks after immunization with UPK3A 65-84 showed high titer serum antibody
responses to UPK3A 65-84 but not Ovalbumin (n=5).
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Figure 5. Type 1 Antibody Isotype Response to UPK3A 65-84. The antibody response
to UPK3A 65-84 was predominantly a type-1 response involving high production of
IgG2a and IgG3, low production of IgG2b and IgG1 (n=4). All error bars show ±SE.
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3.6. Active Induction of EAC in BALB/c mice Immunized with UPK3A 65-84

Active immunization of BALB/c mice with 200 µg of UPK3A 65-84 in CFA
resulted in induction of experimental autoimmune cystitis 5 weeks after immunization.
Immunocytochemical staining for T-cells determinants in the bladder tissue after 5 weeks
after immunization, showed that the bladder infiltrating cells were predominantly T cells
(Figure 6a, right) and that such T cell infiltration was not evident in bladders from control
mice (Figure 6a, left). Hematoxylin and Eosin(H&E) stained bladder sections taken 5
weeks after immunization with UPK3A 65-84 showed extensive perivascular infiltration
(Figure 6b, right) that was not evident in any sections taken from CFA immunized
control mice (Figure 6b, left). The bladder T cell accumulation in UPK3A 65-84
immunized mice was predominantly located under the urothelial epithelium, the area of
lamina propria.
Bladder specific inflammation was demonstrated in mice immunized with UPK3A 6584. qRT-PCR analysis showed significantly elevated gene expression levels of the
inflammatory cytokines, TNFα, IL-17a, IFNγ, and IL-1β in the bladder but not in the
kidney, ovary, uterus, and liver of immunized mice with UPK3A 65-84 compared to
tissues taken from age- and sex-matched naive mice or control mice immunized with
CFA(P<0.001 in all cases) (Figure 7). We clearly determined that the inflammation is
confined to bladder tissue of EAC mice.
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Figure 6. H&E and Immunocytochemical Staining of Bladder Tissues
(A)Immunocytochemical analysis of bladder tissue Immunostaining with CD3 antibody
showed a predominance of T cells in the bladder infiltrates of mice immunized with
UPK3A 65-84 ( right panel) not evident in anti-CD3 stained sections from control mice
immunized with CFA (left panel). Solid bar = 20 μm for sections (B) Hematoxylin and
Eosin stained bladder sections taken 5 weeks after immunization with UPK 3A 65-84
showed extensive perivascular infiltration (right panel) not evident in sections taken from
CFA immunized control mice (left panel). Solid bar =100 μm for sections.
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Figure 7. Bladder Specific Inflammatory Response. Real-time-PCR analysis showed
significantly elevated (P<0.05 in all cases) expression levels of IFNγ, TNFα, IL-1β, and
IL-17A in the bladder but not in the kidney , ovary, uterus, and liver of mice immunized
with UPK3A 65-84 compared to tissues taken from age- and sex-matched naive mice or
control mice immunized with CFA. Error bars show ±SE.

48

3.7. Bladder Dysfunction, IC/PBS phenotypical characterization following active
immunization with UPK3A 65-84
To find out the whether UPK3A 65-84 were able to induce an experimental
autoimmune cystitis, female BALB/c mice were immunized with this peptide and bladder
dysfunction by FVC and pelvic pain were tested 5 weeks later. Functional analysis
showed that 5 weeks after immunization with UPK3A 65-84, BALB/c female mice
showed significantly increased micturition frequencies (Figure 8a) and significantly
decreased mean urine outputs per micturition (Figure 8c) (P<0.0001). Figure 8b-d-shows
the urine production and its frequency of an individual immunized mouse with UPK3A
65-84 and immunized mice with CFA respectively. This observation correlates the
phenotypical features, which are urinary frequency and urgency, seen in human IC/PBS.
The pelvic pain assessment with the most popular non-invasive von Frey Filaments on
the pelvic region revealed that immunized mice with UPK3A 65-84 developed pelvic
pain with the increase response to noxious stimulus as the meaning of decreased
threshold of pain response on the pelvic region as an indicator of referred pain of bladder
organ(p<0.05)(Figure 9).
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Figure 8. Bladder Dysfunction in Mice Immunized with UPK3A 65-84. (A) 24 hour
micturition frequencies were significantly higher 5 weeks after immunization of BALB/c
female mice with UPK3A 65-84 compared to control mice immunized with CFA. (B)
Inversely, urine output/micturition was significantly lower in mice immunized with
UPK3A 65-84 compared to control mice immunized with CFA.* indicates the P
value<0.0001 significantly difference. Error bars show±SE. (C-D) The representative
graphs show the urine production and its frequency of an individual immunized mouse
with UPK3A 65-84 and immunized mice with CFA.

50

Figure 9. Increased Pelvic Pain Response in EAC. The referred hyperalgesia was
examined with von Frey filaments applied to the pelvic region (suprapubic) 5 week after
immunization (n=10). The behaviors that were considered to be as a positive response
are: 1) sharp withdrawal of the abdomen; 2) instant licking and scratching; 3) jumping.
The response frequency was calculated for each filament as the percentage of positive
responses out of 10 stimuli. Each filament was performed for 1-3 seconds with 5-8
seconds intervals between each stimulus of total 10 times. Immunized mice with UPK3A
65-84 developed pelvic pain with the elevated response to stimulus as the meaning of
decreased threshold of pain response on the pelvic region as an indicator of referred pain
of bladder organ(p<0.05) compared to control CFA and naïve(baseline) control.
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3.8. Immunization with UPK3A 65-84 Increases Bladder Weights.

5 five after immunization the bladder weights were measured from BALB/c mice
immunized with UPK3A 65-84 or CFA alone. UPK3A 65-84 immunized mice showed
significantly increased (P<0.001) bladder weight (mg)/body weight (mg) ratios, a simple
but reliable measure of organ inflammation (Figure 10).We observably confirm that
active immunization with UPK3A 65-84 peptide is capable of inducing autoimmune
cystitis in BALB/c female mice.

Figure 10. Immunization with UPK3A 65-84 Increases Bladder Weights. Bladder
weight (mg)/body weight (mg) ratios were significantly higher (P<0.001) in mice
immunized with UPK3A 65-84 compared to controls. Error bars show ±SE.* indicates P
value<0.05.
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3.9. Cystometrogram Analysis of Bladder Dysfunction in EAC Mice

The bladder threshold pressure, peak voiding pressure, resting pressure,
compliance, and mean inter contractile interval were measured during micturition. Figure
11 and 12 shows the representative CMG data of UPK3A 65-84 immunized mice and
CFA alone. Table III shows the CMG analyzed data. Peak voiding pressure which is the
highest pressure throughout micturition was decreased significantly in UPK3A 65-84
immunized mice after 5 weeks immunization compared to CFA injected group.
Threshold pressure, which is the pressure at the beginning of micturition phase, was also
decreased significantly compared to control group. Resting pressure, which is the
pressure after micturition, was significantly decreased in UPK3A 65-84 immunized mice.
The significant decreased bladder compliance, which is calculated by dividing the voided
volume by the variation in bladder pressure throughout the voiding phase, was observed
in UPK3A 65-84 immunized mice. The mean intercontractile intervals were decreased in
EAC mice compared to CFA injected control group.
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Figure 11. Representative Cystometrogram for EAC and Control Group.
Representative images of Cystometrogram of UPK3A 65-84 immunized mice and CFA
alone 5 Week after Immunization. Saline Infusion rate mL/s=0.000277778 or Infusion
rate mL/hr=1.
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Figure 12. Representative Cystometrogram of EAC vs Control. Representative
images of Cystometrogram of UPK3A 65-84 immunized mice and CFA alone 5 Week
after Immunization. Infusion rate mL/s=0.000277778 or Infusion rate mL/hr=1.
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Cystometry Results of EAC mice

UPK3A 65-84 Immunized Group
Control-CFA Group

Resting Pressure,cmH2O
Mean
SD
10.84796
3.05511
12.02088
2.54372
Peak Voiding Pressure, cmH2O

SEM
0.3168
0.43624

P value
0.032

UPK3A 65-84 Immunized Group
Control-CFA Group

39.86806
11.2975
46.57529
5.94939
Threshold Pressure, cmH2O

1.1715
1.02031

0.001

UPK3A 65-84 Immunized Group
Control-CFA Group

22.86892
5.40327
27.53118
6.45137
Bladder Capacity, mL

0.56029
1.1064

0.00007

UPK3A 65-84 Immunized Group
Control-CFA Group

0.0651
0.03558
0.14652
0.07024
Compliance, mL/cmH2O

0.00388
0.01282

0.00001

UPK3A 65-84 Immunized Group
Control-CFA Group

0.00575
0.00331
3.61E-04
0.01104
0.00734
0.00134
Mean Intercontractile intervals, second

0.0005

UPK3A 65-84 Immunized Group
Control-CFA Group

234.35646
534.15138

0.0000007

128.07065
254.64703

13.97365
47.28677

Table 3. Comparisons of Cystometry Results. Cystometry results of EAC mice.5 week
after immunization conscious CMG was performed. Bladder resting pressure, bladder
threshold pressure, peak voiding pressure, bladder capacity, compliance and mean
intercontractile intervals were analyzed on cystometry data of mice immunized with
UPK3A 65-84(n=6), and mice immunized with CFA(n=5). Infusion rate
mL/s=0.000277778 or Infusion rate mL/hr=1.
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3.10.

IC/PBS phenotype occurred following adoptive transfer of CD4+ T-

cells from UPK3A 65-84 Primed Mice.
We determined EAC (transferring the immunologic functionality and features into
naïve host) induction capability of adoptive transferring of isolated CD4+ T cells, CD8+
T cell, B cells, and serum from immunized mice into naïve BALB/c mice. 10 days after
immunization with UPK3A 65-84 peptide or OVA, CD4+ and CD8+ T cells were
isolated and enhanced proliferation with the immunogens, and transferred into naïve
recipients. After 20 days of adoptive transfer, the phenotype of EAC bladder dysfunction
tested with FVC showed that 24 hour micturition frequencies were significantly higher in
mice with peptide specific CD4+ T cells-transferred compared to control-OVA induced
T-cell transferred. Inversely, urine output/micturition was significantly lower in mice
with peptide specific CD4+ T cells-transferred compared to control mice (Figure 13a-b).
However, no phenotypical signs of IC/PBS occurred in FVC measurements after
transferring the peptide induced CD8+ T cells into naïve BALB/c mice recipients
compared to control OVA- mediated CD8+ T cells transferred (Figure 14). Similarly, the
transfer of collected sera from 5 weeks after immunized mice with UPK3A 65-84 or
Ovalbumin, no micturition abnormalities associated to EAC phenotype observed
compared to control (Figure 15). The passive transfer of B-Cells from immunized mice
with UPK3A 65-84 did not show differences in voiding frequency and micturition
output/voiding compared to control(P values 0.77, and 1 respectively)(Figure 16).
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Figure 13. Adoptive Transfer of enriched CD4+T cells developed EAC. The
phenotype of EAC development was tested with FVC after 20 days of adoptive transfer
(A) Bladder dysfunction resembling IC/PBS phenotype in mice with peptide specific
CD4+ T cells-transferred showed that 24 hour micturition frequencies were significantly
higher compared to control-OVA induced T-cell transferred(n=10). (B) Inversely, urine
output/micturition was significantly lower in mice with peptide specific CD4+ T cellstransferred compared to control mice.
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Figure 14. Adoptive Transfer of CD8+T cells, no Phenotypical Changes in FVC. No
phenotypical signs of IC/PBS occurred in FVC measurements after transferring the
peptide induced CD8+ T cells into naïve BALB/c mice recipients compared to control
OVA- mediated CD8+ T cells transfer.
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Figure 15. Sera Transfer from Immunized Mice to Naive Host. 5 weeks after
immunization collected and pooled sera from immunized mice with UPK3A 65-84 or
Ovalbumin, transferred into naïve BALB/c recipients and the 20 days later FVC
measured showed no differences between groups.
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Figure 16. Passive Transfer of B-cells from Mice Immunized with UPK3A 65-84 to
Naive Recipient. 5 weeks after immunization with UPK3A 65-84 or Ovalbumin, the
purified B-cells transferred into naïve BALB/c recipients and the 20 days later FVC
measurement showed no differences between groups.
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3.11.

Pelvic Pain Response Following Adoptive Transfer of CD4+ T-cells

from UPK3A 65-84 Primed Mice.
Pelvic pain which is the most prominent phenotype of IC/PBS, was examined
with von Frey filaments by administration onto the pelvic region (suprapubic) at day-510-20-30 after passive transfer of the UPK3A 65-84 primed CD4+ and CD8+ T cells, B
cells and sera comparing with OVA primed CD4+ and CD8+ T cells, and sera transferred
group, into naïve BALB/c recipients. UPK3A 65-84 primed CD4+ T cells revealed
increase pain response to stimulus compared to control mice transferred with CD4+ T
cells specific for OVA, as the indicator of decreased threshold of referred pain of bladder
organ on the pelvic region (Figure 17). On the other hand, the passive transfer of peptide
induced CD8+ T cells into naïve BALB/c mice recipients showed no difference in pain
assessment compared to control OVA- mediated CD8+ T cells transfer (Figure 18). The
pooled sera taken from 5 weeks after immunization of mice with each immunogens were
injected into naive recipient BALB/c female hosts. The pain measurements at 5, 10, 20,
30 days were not different compared to control groups (Figure 19). The passive transfer
of B-Cells from immunized mice with UPK3A 65-84 did not show differences in pelvic
pain responses compared to control groups (Figure 20).
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Figure 17. Adoptive Transfer of enriched CD4+ T cells from UPK3A 65-84
immunized mice revealed increase pelvic pain response. Pelvic pain which is the most
prominent phenotype of IC/PBS, was examined with von Frey filaments applied to the
pelvic region (suprapubic) at day 5, 10, 20, and 30 after transferring the UPK3A 65-84
primed CD4+ and CD8+ T cells and serum comparing with OVA primed CD4+ and
CD8+ T cells, and sera transferred group into naïve recipients(n=10). Adoptive transfer
of UPK3A 65-84 primed CD4+ T cells revealed increase response to stimulus after 5, 10,
20 and 30 days, compared to control mice transferred with CD4+ T cells specific for
OVA, as the indicator of decreased threshold of referred pain of bladder organ on the
pelvic region.
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Figure 18. There is no pelvic pain response after adoptive transfer of CD8+ T cells.
The pelvic pain phenotype of IC/PBS was not occurred by testing von Frey filaments on
the referred area of bladder pain (suprapubic) at day 5, 10, 20, and 30, after transferring
the peptide induced CD8+ T cells into naïve BALB/c mice recipients compared to control
OVA- mediated CD8+ T cells transfer.
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Figure 19. There is no pelvic pain response after sera transfer from mice immunized
with UPK3A 65-84.The sera samples taken from 5 weeks after immunization with each
immunogenic peptide (Ovalbumin and UPK3A 65-84), the collected and pooled sera
were injected [3 injections of 200 μl per mice, i.v/i.p injection, every other day] into
naive recipient BALB/c female hosts for determining the ability to mediate EAC. After
the 5, 10, 20, 30 days pain measurements, no difference was observed to stimulus in
transferred groups compared to control groups.
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Figure 20. Passive Transfer of B-cells from mice immunized with UPK3A 65-84 into
naive host did not developed pelvic pain response. Passive Transfer of B-cells from
UPK3A 65-84 immunized mice into naïve BALB/c host did not revealed pelvic pain
response by testing von Frey filaments on the referred area of bladder pain at day 5, 10,
20, and 30 compared to control groups.
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Thus, the passive transfer of CD4+ T cells, isolated from LNCs of UPK 3A 65-84
immunized mice, developed EAC in naïve host BALB/c mice showing the phenotypical
features of IC/PBS; frequent urination, decrease output per micturition and increase
pelvic pain response to von Frey monofilament stimulus.
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CHAPTER IV
DISCUSSION

Our study reveals that an UPK3A peptide specific CD4+ T-cell autoimmunity
mediates painful bladder dysfunction in mice that mimics human IC/PBS. The
pathophysiology of IC/PBS remains puzzling. Advancement in addressing IC/PBS has
been overwhelmingly slow due to a lack of understanding of the underlying
pathophysiology and lack of markers for the disease. The current approaches in our
scientific area mostly focus on merge clinical practice and translational thus stressing the
significance of translational models. Almost 20 animal models have been scrutinized for
two decades which resembles somewhat IC/PBS phenotype (Westropp and Buffington
2002). One of the limitations in IC/PBS research has been the lack of an appropriate
animal model. The NIH (National Institutes of Health) has launched a number of
initiatives in both clinical and basic science of IC/PBS over the past 15 years without
making a meaningful impact. Suffice it to say that IC/PBS remains one of the top
priorities for NIH-NIDDK as a disease that could benefit from a realistic animal model
and translational research.
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The earlier animal models have been developed through different approaches
such as inducing inflammation by transurethral application of irritant or immune
stimulants into urinary bladder, systematic and environmentally caused irritations (e.g.,
acetone, glycerol, mustard oil, acetic acid, cyclophosphamide [CYP]),

autoimmune

strategies (bladder homogenate, URO-OVA or URO-OVA/OT-I, UPK2 protein)(Liu,
Evanoff et al. 2007; Altuntas, Daneshgari et al. 2008; Lin, Liu et al. 2008; Liu, Deyoung
et al. 2008; Rudick, Schaeffer et al. 2008; Altuntas, Daneshgari et al. 2011). Transgenic
EAC model of URO-OVA mice fabricate a membrane structure of Antigen-Ovalbumin
(OVA) like a self-antigen on the urothelium derived by Uroplakin II gene promoter and
then the bladder autoimmune cystitis was generated through the transfer of

OVA-

specific OT-I CD8+ T-cells to this mouse (Liu, Evanoff et al. 2007; Liu, Deyoung et al.
2008). The disadvantage of this model is that OVA is not endogenous antigen of bladder
and the urodynamic assessment of the bladder or bladder dysfunction, and pelvic pain
associated to IC/PBS phenotype have not been characterized and demonstrated. Even
though CYP- employed cystitis model is well-described and broadly study for chronic
cystitis, the pathogenesis does not fit the IC/PBS of human(Vera, Iczkowski et al. 2008).
A spontaneous model of IC/PBS was described in feline(Buffington 2004), however this
was not applied extensively in scientific community due to cost and handling problems.
Autoimmunity of IC/PBS has been suspecting due to concomitant occurrence
with some autoimmune disorders for instance; systemic lupus erythematosis(SLE),
rheumatoid arthritis, ulcerative colitis, thyroiditis, Sjögren syndrome and fibromyalgia
syndrome (Keay, Zhang et al. 1997; Ochs 1997; Lorenzo Gomez and Gomez Castro
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2004; van de Merwe 2007). And also the relatively high occurrence of antibodies in
patients with IC (van de Merwe 2007), the increase demonstration of CD4 and CD8 TCells, B cells, plasma cells(MacDermott, Miller et al. 1991; Christmas 1994), and
inappropriate expression of HLA-DR in the bladder biopsies of IC patients(Christmas
and Bottazzo 1992).
The strategy of mounting an inflammatory T-cell response against carefully
selected antigens that are expressed only in the targeted organ has utilized to the
establishment of practical experimental autoimmune animal models for studying a variety
of human diseases including autoimmune encephalomyelitis(EAE)-Multiple Sclerosis
(Tuohy, Lu et al. 1989; Yu, Johnson et al. 1996), autoimmune inner ear disease (Solares,
Edling et al. 2004), autoimmune oophoritis -premature ovarian failure(Altuntas, Johnson
et al. 2006) , and autoimmune myocarditis-dilated cardiomyopathy (Jane-wit, Yu et al.
2002).
The similar strategies mounting an inflammatory T cell response to targeted
tissues were reported in the employment of bladder homogenate and bladder specific
protein UPK2 (Lin, Liu et al. 2008), (Altuntas, Daneshgari et al. 2011) showing induction
of autoimmune mediated EAC in SWXJ mice resembling the human IC urodynamicaly.
The disadvantage of immunization with bladder homogenate is the possible induction of
non-specific and systemic immune reaction alongside the bladder tissue because of the
composition of bladder non-specific or specific antigens. The IC mice model
immunization with bladder specific recombinant UPK2 protein mice exhibited bladder
specific T cell mediated autoimmunity and significant proof bladder dysfunction in
regard to increased frequency of urination and decrease urine output per voiding (Lin, Liu
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et al. 2008; Altuntas, Daneshgari et al. 2011); however, this EAC mouse model was not
revealed pelvic pain response to noxious stimulus with von Frey Filaments, that missing
one of the major symptoms of IC/PBS phenotypes.

These observed phenotypical

characteristics and urodynamic abnormalities in those mice models were somewhat
similar with IC/PBS symptoms seen in human, thus we aimed to create more specific
autoimmunity targeting a bladder specific protein, which could induce all major
phenotypical features of IC/PBS, especially the pelvic pain phenotype. In view of that, it
is necessary for an animal model that merges all phenotypical properties as observed in
human IC/PBS together with frequency, urgency, pelvic pain along with bladder
specificity and high induction rate of IC/PBS phenotype.
In our present study, we evaluated immunogenicity of the peptides derived from
bladder specific Uroplakin proteins in different mice strains. We found that a 20-mer
peptide from UPK3A is highly immunogenic and specifically elicits CD4+ T-cell
mediated Th1 immune response in BALB/c mice inducing EAC along with bladder
confined inflammation. We verified inflammation in bladder by revealing the increase
expressions of proinflammatory cytokines and the presence of clusters of T-cells in the
bladder following immunization. Moreover, the significantly increased bladder weight to
body weight ratios are basic and simple indicator for inflammation. These findings point
out that immunization of BALB/c mice with UPK3A 65-84 incites an organ specific
autoimmune disorder described through inflammation restricted to the bladder that
continually directs to bladder dysfunction parallel to that examined in Uroplakin III or IInull mice (Aboushwareb, Zho et al. 2007). Subsequently, we tested bladder function and
pelvic pain response whether active immunization with UPK3A 65-84 can induce or
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initiate an IC/PBS phenotype. The phenotypical characteristics of our current model were
seen 5wk after active immunization with UPK3A 65-84. The mice immunized with
UPK3A 65-84 showed significantly elevated urinary frequencies, decreased urine outputs
per void, and increased pelvic pain response, which resemble all three major symptoms
of IC/PBS. Moreover, decrease intercontractile intervals and bladder compliance that
were observed on CMG measurement in EAC model, also correlate with the
physiological alterations seen the human IC/PBS. Correspondingly, the passive or
adoptive transfer of UPK3A 65-84 stimulated CD4+ T-cell mediates EAC in BALB/c
naïve recipients manifesting significantly detectable pelvic pain response, increased
micturition frequency, and decreased output per micturition, similar to the
symptomatology observed in IC/PBS. Our data indicates that the bladder dysfunction and
increase pelvic pain response occurring in EAC is due to CD+4 T-cell mediated
autoimmune inflammation of the bladder tissue. We elucidated a potential move toward
to examine referred hyperalgesia by von Frey Filaments on pelvic region (Laird,
Martinez-Caro et al. 2001). 5 weeks after active immunization and 5, 10, 20, 30 days
after the adoptive transfer of CD+4 T-cells, for pelvic and urinary bladder pain
assessment, we found an enhanced response to a painful stimulus and a painful reaction
to a normal stimulus.
The significance of our model is that just one single peptide, UPK3A 65-84,
induces T-Cell dependent autoimmune mediated EAC with higher bladder specificity,
accurately reflecting the urodynamic symptoms and chronic pelvic pain of IC/PBS
phenotype. The further characterization of the pelvic pain mechanism in this model is
needed to investigate. The role of mast cells in the induction of cystitis pain has already
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revealed (Rudick, Bryce et al. 2008; Rudick, Schaeffer et al. 2009). For future studies the
mast cells and T-cells involvement in pelvic pain development in IC/PBS model could be
investigated.
In this mouse model, we clearly characterized and showed a targeted
autoimmunity against bladder specific protein, UPK IIIA, induces a new type of EAC.
This bladder specific autoimmunity can be used in an actively way to prevent the
development of bladder cancers and retardation of existing tumors. It is already known
that the highly expressed antigens in tumor are appropriate target for cancer
immunotherapies. It was also suggested that the organ or tissue specific antigens that are
produced through normal tissue or their originated cancer cells could be targeted for
cancer vaccination (Jaini, Kesaraju et al. 2010; Tuohy 2010; Altuntas, Jaini et al. 2012).
It was proposed that peripheral self-tolerance mechanisms possibly hinder the
endogenous immune reaction to cancer, and it is essential to breakdown to elicit clinically
applicable antitumor response (Dudley, Wunderlich et al. 2002; Dudley, Wunderlich et
al. 2005). The effect of immunotherapy and autoimmunity regarding to tumor retardation
and autoimmune reactivity to normal tissues were studied in some clinical immunemediated treatments, and also in pre-clinical immunotherapy models (Huber and Wolfel
2004; Dudley, Wunderlich et al. 2005) (Overwijk, Lee et al. 1999; Bettinotti, Panelli et
al. 2003; Phan, Yang et al. 2003). It was tested in mice that the targeted autoimmune
response to organ specific proteins can hinder or treat tumor development in that organ or
tissues. The study in autoimmune mice models, the tumor development of autochthonous
ovarian granulosa cell tumors in SJL.AMH-SV40Tag transgenic mice was hindered in
immunized group with Inhibin alpha 215-234 peptide and also, the therapeutically

73

vaccinated group that had ovarian granulosa cell tumors showed significantly reduction
of tumor growth(Altuntas, Jaini et al. 2012). In another study, breast autoimmunity was
developed immunization with the recombinant mouse mammary-specific differentiation
protein antigen (α-lactalbumin), and assessed the effectiveness of immunization with αlactalbumin on cancer development in prophylactic and therapeutic approaches. It was
demonstrated that immunoreactivity against alpha-lactalbumin resulted in significant
prevention and treatment against autochthonous tumor development in breast cancer
mouse models, and against 4T1 transplantable breast tumors in BALB/c mice (Jaini,
Kesaraju et al. 2010).

Recently, the Tumor vaccine development trials with

immunogenic cancer/testis (CT) antigens produced in normal gametogenic tissues and
in various cancers, MAGE-A3 (melanoma antigen A3) and NY-ESO-1 have been
conducted, and suggested that these antigens could be used for antigen-specific adoptive
T-cell transfer for the cancer immunomodulation (Parmigiani, Bettoni et al. 2006;
Caballero and Chen 2009). NCI (National Cancer Institute) Researchers revealed the
success of immunotherapy method for melanoma treatment showing significant
shrinkage in the tumor size of melanoma patients who have progressive melanoma
unresponsive to former treatments and autoimmunity targeted against normal
melanocytes was detected in 75% of the adoptively T-cell treated patients who showed
tumor inhibition (Dudley, Wunderlich et al. 2005).
Uroplakins (UPKI, II, and III) are integral membrane proteins uroepithelium
(Kong, Deng et al. 2004) vastly and specifically produced in bladder tissue. Uroplakins
might be effective as an anti-cancer vaccine development for targeting an autoimmune
attack against bladder cancers. The expression of UPK III bladder cancer were showed
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that there is 60% (21/35) in the primary tumors and 53% in (17/32) the metastatic tumor
of human urothelial carcinomas (Kaufmann, Volmerig et al. 2000). Several studies have
validated the stable expression of UPKII in human bladder cancer cell lines (Wu, Kakehi
et al. 2005). UPKII promoter driven expressions of SV40 led urothelium cancer in the
bladder of transgenic mouse (Saban, Towner et al. 2007). It was suggested that
Uroplakins are also able to be suitable for creating tissue specific vectors designed for
bladder cancer gene therapy (Zhu, Zhang et al. 2004; Zhu, Zhang et al. 2004).

Overall, we have established a bladder-specific autoimmunity of UPK3A 65-84
immunized mice with a high induction rate of EAC, and propose that our model is a
remarkably practical model for future exploration of mechanistic event in pathogenesis
and therapeutic intervention of IC/PBS and the facts gained in this model gives further
vision to test different strategies for autoimmune mediated regulation of bladder cancer.
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